Jitka Fucikova1
Zdenka Gasova1
Katerina Kubackova1
Daniela Rozkova1
Learn More
  • Michal Podrazil, Rudolf Horvath, Etienne Becht, Daniela Rozkova, Pavla Bilkova, Klara Sochorova +12 others
  • 2015
PURPOSE We conducted an open-label, single-arm Phase I/II clinical trial in metastatic CRPC (mCRPC) patients eligible for docetaxel combined with treatment with autologous mature dendritic cells (DCs) pulsed with killed LNCaP prostate cancer cells (DCVAC/PCa). The primary and secondary endpoints were safety and immune responses, respectively. Overall(More)
  • 1